Introduction

Decoding HLA Complexity for Advanced Immunogenetics and Cell Therapy

The Human Leukocyte Antigen (HLA) system represents the most highly polymorphic region in the human genome. For decades, standard HLA typing was sufficient for basic research. However, the rapid emergence of advanced cell therapies, such as universal (allogeneic) CAR-T cell engineering, has fundamentally shifted the requirements for genetic precision.

To create "off-the-shelf" universal cell therapies, researchers typically utilize gene editing tools to knock out specific HLA class I molecules on donor cells, preventing immune rejection. Ensuring the absolute precision of this edit, and accurately evaluating potential off-target effects, requires a flawless understanding of the target sequence background. Even a single nucleotide polymorphism (SNP) in an allele can disrupt sgRNA binding or lead to unintended structural variations.

This is where standard typing falls short and high-resolution HLA typing becomes a critical prerequisite. Precise 4-digit to 8-digit resolution not only identifies synonymous mutations in the coding regions but also maps critical variations in non-coding introns and untranslated regions (UTRs). By establishing this absolute baseline, researchers can confidently design highly specific guides for downstream CRISPR screening sequencing, ensuring the developmental safety and efficacy of next-generation cellular constructs.

Applications

Diverse Applications in Gene Editing and Immunogenetics

The necessity for unambiguous HLA sequence data extends far beyond basic typing. Our high-resolution sequencing services support diverse, cutting-edge research applications across academic institutes and biopharma laboratories.

Universal CAR-T and Cell Therapy Engineering

Accurately sequence target HLA loci prior to CRISPR/Cas9 knockout procedures. High-resolution data is essential to design highly specific sgRNAs, maximize on-target cleavage efficiency, and comprehensively map potential off-target liabilities in engineered immune cells.

Complex Immunogenetics Research

Unravel the intricate relationship between specific HLA haplotypes and autoimmune mechanisms. By pairing high-resolution HLA profiling with comprehensive BCR and TCR sequencing, researchers can map how specific genetic backgrounds shape the adaptive immune repertoire.

Pharmacogenomics and Hypersensitivity Studies

Investigate the genetic basis of severe adverse drug reactions (ADRs). Precise identification of specific alleles is fundamental for discovering novel biomarkers linked to drug hypersensitivity in preclinical models.

Post-Editing Cell State Characterization

Following targeted HLA modification, researchers frequently utilize downstream single-cell RNA sequencing to evaluate the global transcriptomic consequences of the edit, ensuring the cells retain their desired therapeutic phenotype without unintended stress responses.

Technology Platforms

Comprehensive Technology Platforms: NGS, Sanger, and Long-Read

There is no single "silver bullet" for sequencing the highly polymorphic HLA region. To provide zero-compromise precision, we offer a comprehensive suite of three distinct sequencing technologies. This allows us to perform orthogonal cross-validation and tailor our approach strictly to your project's budget, throughput, and resolution requirements.

Comparison Dimension NGS (Next-Generation Sequencing) Sanger Sequencing Long-read Sequencing
Primary Advantage High-throughput, cost-effective screening Unmatched accuracy (99.999%), "Gold Standard" Full-length amplification, no fragmentation
Resolution Limit Up to 6-digit Up to 6-digit (highly targeted) Up to 8-digit resolution
Loci Coverage Broad (11 classical loci) Targeted (Specific single loci) Broad (11 classical loci)
Phase Ambiguity Susceptible to cis/trans phase issues Requires TA cloning for heterozygotes Inherently resolves phase ambiguities
Ideal Use Case Large-cohort screening, multi-loci profiling CRISPR target validation, resolving rare alleles Complex haplotypes, ultimate precision

Solution Selection Strategy

Consult a Scientist for Platform Selection

Workflow

End-to-End Workflow: Resolving Homozygous and Heterozygous Alleles

The true challenge of HLA typing using the gold-standard Sanger method lies in addressing the extreme heterozygosity of the human genome. When a subject carries two distinctly different alleles at the same HLA locus, direct sequencing generates overlapping chromatogram signals, rendering accurate base-calling impossible.

To overcome this, our laboratory has optimized highly specialized workflows for both homozygous and heterozygous scenarios, ensuring clean, unambiguous data delivery.

1. Homozygous Workflow: Streamlined Direct Sequencing

Streamlined direct sequencing workflow for homozygous HLA alleles.
Streamlined direct sequencing workflow for homozygous HLA alleles.

For homozygous samples (where both alleles at a locus are identical), we employ an accelerated direct sequencing pipeline:

2. Heterozygous Workflow: Precision TA Cloning Separation

Precision TA cloning workflow for resolving heterozygous HLA alleles.
Precision TA cloning workflow for resolving heterozygous HLA alleles.

To resolve overlapping signals in heterozygous samples, we utilize classical, highly rigorous molecular cloning techniques to physically separate the two alleles prior to sequencing:

Bioinformatics

Advanced Bioinformatics for High-Resolution Alignment

Generating high-quality raw sequence data is only the first half of the equation; aligning highly polymorphic, homologous sequences requires exceptional computational power. Standard open-source algorithms often struggle with HLA data, frequently misaligning reads and generating false-positive novel alleles due to the high density of SNPs.

Our proprietary bioinformatics pipeline has been meticulously developed and patented to overcome these specific challenges.

Deliverables

Typical Demo Reports and Deliverables

We believe in complete data transparency. Regardless of the chosen platform, our deliverables are designed to integrate seamlessly into your downstream bioinformatic environments and research documentation.

Demo reports of high-resolution HLA typing and sequencing traces.
Unambiguous typing results from Sanger, NGS, and Long-read platforms.

Case Study

Case Study: Resolving Complex HLA Haplotypes

High-resolution HLA typing is a fundamental enabler for the next generation of cellular therapies, particularly in the quest to engineer "superdonor" cells that evade immune detection across broad populations.

Developing universal, allogeneic cell therapies requires identifying unique cell sources or executing precise genomic edits to minimize HLA-mediated immune rejection. Finding rare donors who are homozygous for multiple HLA loci (e.g., HLA-A, B, and C) provides an incredible foundation for creating "synthetic superdonors." However, identifying these individuals requires absolute certainty in typing, as conventional low-resolution methods cannot distinguish true homozygosity from undetected rare heterozygous variants.

As detailed in recent breakthrough research regarding synthetic superdonors, investigators utilized high-resolution typing strategies to meticulously screen candidate genomic materials. By employing advanced sequencing, they could unambiguously sequence the full coding and non-coding regions of classical HLA class I loci, confirming true double and triple homozygosity.

The high-resolution data provided undeniable molecular proof of the homozygous genotypes. For instance, detailed analyses derived from methodologies similar to those described in Identification of HLA-A, HLA-B, and HLA-C triple homozygous and double homozygous donors demonstrate how unambiguous typing allows researchers to select optimal donor cells. These cells serve as the ideal biological chassis for subsequent CRISPR-Cas9 engineering, where the remaining distinct HLA alleles are precisely targeted for knockout.

Deploying orthogonal, high-resolution HLA typing—such as combining NGS screening with Sanger or Long-read validation—is an indispensable strategy. It provides the essential, high-fidelity genetic blueprint required to execute safe and effective gene editing, ultimately paving the way for advanced, immune-evasive cellular medicinal products.

Sample Requirements

Sample Requirements and Guidelines

To guarantee the highest data quality and eliminate sequence artifacts, stringent sample quality control is enforced. We accept a variety of sample formats, processed according to the guidelines below:

Sample Type Minimum Input Quality/Purity Delivery State Shipping Condition
Genomic DNA (gDNA) ≥ 1 μg (Qubit quantified) OD260/280 = 1.8-2.0 Intact main band, no degradation Dry Ice
Peripheral Blood ≥ 2 mL Collected in EDTA tubes Unfrozen, fresh whole blood Blue Ice (4°C)
Tissue Samples ≥ 50 mg Flash-frozen immediately Solid tissue Dry Ice (-80°C)
Cultured Cells ≥ 2 × 106 cells Centrifuged cell pellet Supernatant removed Dry Ice (-80°C)

Note: For highly specialized samples or limited-input scenarios, please contact our technical team to discuss customized DNA extraction protocols.

FAQ

Frequently Asked Questions

All services and products described herein are strictly for Research Use Only (RUO). They are not intended for use in diagnostic procedures, clinical decision-making, direct human therapeutic interventions, or any regulatory clinical trial applications.

For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.
Inquiry
For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.

CD Genomics is transforming biomedical potential into precision insights through seamless sequencing and advanced bioinformatics.

Copyright © CD Genomics. All Rights Reserved.
Top